Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
111 Inc (YI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: YI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.3% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.07M USD | Price to earnings Ratio - | 1Y Target Price 5.96 |
Price to earnings Ratio - | 1Y Target Price 5.96 | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 4.14 - 12.90 | Updated Date 06/29/2025 |
52 Weeks Range 4.14 - 12.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.17 |
Earnings Date
Report Date 2025-06-19 | When - | Estimate - | Actual -0.2802 |
Profitability
Profit Margin -0.48% | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -0.03% | Return on Equity (TTM) -7.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19534374 | Price to Sales(TTM) - |
Enterprise Value 19534374 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 37.4 | Shares Outstanding 5067440 | Shares Floating 70009558 |
Shares Outstanding 5067440 | Shares Floating 70009558 | ||
Percent Insiders 15.84 | Percent Institutions 23.69 |
Upturn AI SWOT
111 Inc
Company Overview
History and Background
111, Inc. (YI) was founded in 2010. It operates as an integrated online and offline healthcare platform in China. The company focuses on providing pharmaceutical products and healthcare services to consumers, pharmacies, and medical professionals.
Core Business Areas
- B2C Online Pharmacy: Operates an online retail pharmacy platform offering a wide range of prescription and over-the-counter drugs, healthcare products, and medical devices directly to consumers.
- B2B Pharmacy Distribution: Distributes pharmaceutical products and medical supplies to pharmacies, providing them with access to a large inventory and efficient logistics solutions.
- Online Doctor Consultation and Digital Healthcare Services: Provides online medical consultation services, chronic disease management programs, and other digital healthcare solutions to patients.
Leadership and Structure
The leadership team includes Yu Gang, Chairman and Co-CEO, and Junling Liu, Co-CEO. The organizational structure includes departments for e-commerce, supply chain, marketing, technology, and finance.
Top Products and Market Share
Key Offerings
- Prescription Drugs: Offers a wide selection of prescription drugs through its online pharmacy. Market share data is fragmented and difficult to ascertain precisely but competition includes JD Health and Alibaba Health. Revenue from prescription drugs constitutes a significant portion of total revenue.
- Over-the-Counter (OTC) Medications: Sells a variety of OTC medications through its online platform. The OTC market is highly competitive with many local and international players. Again, market share data is difficult to obtain.
- Healthcare Products: Provides healthcare products such as vitamins, supplements, and medical devices. Competition includes general e-commerce platforms such as Taobao and Tmall.
Market Dynamics
Industry Overview
The healthcare industry in China is experiencing rapid growth, driven by factors such as an aging population, increasing healthcare awareness, and government support for online healthcare services. The online pharmacy segment is particularly competitive, with increasing adoption by consumers.
Positioning
111, Inc. positions itself as an integrated online and offline healthcare platform, aiming to provide comprehensive healthcare solutions to consumers, pharmacies, and medical professionals. It aims to differentiate itself through its extensive product portfolio, efficient supply chain, and innovative digital healthcare services.
Total Addressable Market (TAM)
The total addressable market for healthcare products and services in China is substantial and growing. Estimates vary, but it is projected to reach hundreds of billions of dollars in the coming years. 111 Inc. is positioned to capture a portion of this TAM through its various business segments.
Upturn SWOT Analysis
Strengths
- Integrated online and offline platform
- Extensive product portfolio
- Strong relationships with pharmaceutical companies
- Growing user base
- Established brand recognition in the Chinese market
Weaknesses
- High operating expenses
- Dependence on regulatory approvals
- Intense competition
- Profitability concerns
- Relatively small market share compared to larger players
Opportunities
- Expanding online healthcare market
- Increasing demand for chronic disease management solutions
- Partnerships with hospitals and clinics
- Development of innovative digital healthcare services
- Further penetration into lower-tier cities
Threats
- Regulatory changes
- Increased competition from larger players
- Price wars
- Data security and privacy concerns
- Economic slowdown in China
Competitors and Market Share
Key Competitors
- JD Health (9618.HK)
- Alibaba Health (0241.HK)
- Ping An Good Doctor (1833.HK)
Competitive Landscape
111 Inc. faces intense competition from larger, more established players in the online healthcare market. Its advantages include its integrated platform and focus on digital healthcare services, while its disadvantages include its relatively smaller scale and profitability concerns.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data would require real-time financial data feeds to generate an accurate response.
Future Projections: Future projections from analysts would require real-time financial data feeds from analysts to generate an accurate response.
Recent Initiatives: Recent initiatives include expanding its online pharmacy platform, strengthening its supply chain capabilities, and launching new digital healthcare services.
Summary
111 Inc. is an integrated online and offline healthcare platform in China that faces intense competition. The company has a good range of products and has expanded its digital health offerings. A key area of weakness is a lower market share and profitability concerns as it faces larger and established players. They need to carefully manage regulations, price wars, and data security risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 111 Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-09-12 | Co-Founder, Acting CFO, Chairman & CEO Mr. Junling Liu | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1238 | Website https://corporate.111.com.cn |
Full time employees 1238 | Website https://corporate.111.com.cn | ||
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides pharmaceutical products and other merchandise. In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool. Further, it provides drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.